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Background: The next generation magnetic nanoparticles (MNPs) with theranostic applications
have attracted significant attention and will greatly improve nanomedicine in cancer therapeutics.
Such novel MNP formulations must have ultra-low particle size, high inherent magnetic
properties, effective imaging, drug targeting, and drug delivery properties. To achieve these
characteristic properties, a curcumin-loaded MNP (MNP-CUR) formulation was developed.
Methods: MNPs were prepared by chemical precipitation method and loaded with curcumin (CUR)
using diffusion method. The physicochemical properties of MNP-CUR were characterized using
dynamic light scattering, transmission electron microscopy, and spectroscopy. The internalization
of MNP-CUR was achieved after 6 hours incubation with MDA-MB-231 breast cancer cells.
The anticancer potential was evaluated by a tetrazolium-based dye and colony formation assays.
Further, to prove MNP-CUR results in superior therapeutic effects over CUR, the mitochondrial
membrane potential integrity and reactive oxygen species generation were determined. Magnetic
resonance imaging capability and magnetic targeting property were also evaluated.
Results: MNP-CUR exhibited individual particle grain size of ∼9 nm and hydrodynamic average
aggregative particle size of ∼123 nm. Internalized MNP-CUR showed a preferential uptake in
MDA-MB-231 cells in a concentration-dependent manner and demonstrated accumulation
throughout the cell, which indicates that particles are not attached on the cell surface but
internalized through endocytosis. MNP-CUR displayed strong anticancer properties compared
to free CUR. MNP-CUR also amplified loss of potential integrity and generation of reactive
oxygen species upon treatment compared to free CUR. Furthermore, MNP-CUR exhibited
superior magnetic resonance imaging characteristics and significantly increased the targeting
capability of CUR.
Conclusion: MNP-CUR exhibits potent anticancer activity along with imaging and magnetic
targeting capabilities. This approach can be extended to preclinical and clinical use and
may have importance in cancer treatment and cancer imaging in the future. Further, if these
nanoparticles can functionalize with antibody/ligands, they will serve as novel platforms for
multiple biomedical applications.
Keywords: magnetic nanoparticles, drug delivery systems, magnetic resonance imaging,
nanomedicine, cancer therapeutics, biomedical applications

Introduction
Breast cancer is a commonly diagnosed cancer among women in the United States.
It is estimated that 230,480 women were diagnosed with, and 39,520 women died
from, breast cancer in 2011 in the United States.1 Basal-like breast cancer accounts for
15% of all breast cancers and has a poor prognosis. The majority of these cancers are
referred to as triple-negative breast cancers because they do not over express estrogen
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receptor, progesterone receptor, or human epidermal growth
factor receptor 2.2,3 Chemotherapy is an effective option to
treat such cancers; however, chemotherapy is always associated with several sets of side effects.4–7 To overcome/avoid
issues with side effects, natural compounds which are used
as daily food ingredients may be an alternative option.
Among many food ingredients, curcumin (CUR), a natural
diphenol extracted from the ground rhizomes of Curcuma
longa, possesses a number of potentially beneficial biological
characteristics including anticancer and chemoprevention
properties.8 MDA-MB-231 cancer cells are one example of
a triple-negative breast cancer and are highly metastatic in
nature. CUR can effectively upregulate p53, p21, and p27
and downregulate cyclin E; thus, cell cycle arrest occurs at
the G1 phase in these cancer cells.9 CUR also decreases cell
viability and anchorage independency of MDA-MB-231
cancer cells by induction of apoptosis and inhibits constitutive
STAT3 signaling.10 Another study confirmed that CUR
enhances cellular localization and phosphorylation, induces
DNA damage and modulates BRCA1 in triple-negative breast
cancer cells.11 Additionally, synergistic antiproliferation
effects of CUR were observed when used in conjunction with
chemotherapeutic drugs or radiation.12–14 A recent review
article suggests the specific role of CUR towards cancer
cells versus normal cells.15 Specifically, CUR does not show
significant toxicity towards normal human cells. However,
successful implementation of CUR into the clinical arena
must overcome issues related to its solubility, degradation in
physiological medium, and rapid metabolism.16 This can be
achieved through advanced drug delivery systems.16,17 Recent
studies demonstrate CUR entrapped or encapsulated in
nanocarriers, such as polymer nanoparticles, nanoassemblies,
and self-assemblies, can enhance internalization/localization
and thus induce cytotoxicity and apoptosis in cancer
cells.18–22 Similarly, CUR nanoformulations (nanomedicine
of CUR) based on conjugate, emulsion, lipid, polymer,
and gel nanoparticles have been proposed for improving
therapeutic benefits and sensitization for chemotherapy and
radiation.16,17,23
Magnetic nanoparticles (MNPs; mostly iron oxide nanoparticles) are widely used in various medical applications.
MNPs have been utilized as nanocarriers for drugs, contrast
imaging agents in magnetic resonance imaging (MRI), in
local hyperthermia, and magnetic targeting.24,25 However,
high aggregation of MNPs is a common problem. High
surface-to-volume ratios and van der Waals forces trigger
opsonization and therefore, present a major obstacle for
biomedical applications. This phenomenon can be altered
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by engineering the surface of the MNPs through various
stabilizer coatings including surfactants and synthetic and
natural polymers.25 Additionally, some reports suggest that
some polymer coatings on the surface of MNPs can change
the contrast imaging properties appropriate for both T1 and
T2 imaging.26
Advances in cancer nanotechnology increase the use
of novel therapeutic strategies such as nanotheranostics,
which utilize individualized diagnostic therapy. 27 The
interest here was to develop a magnetic nanoformulation
without compromising its basic imaging and drug delivery
characteristics. To date, a wide variety of modalities have
been formulated with MNP platforms that contribute not
only to drug delivery but also exhibit photothermal therapy,
thermosensitive chemotherapy, and visible/luminescence/near
infrared/multimodal imaging.26,28,29 Such nanoformulation
applicability relies on the design and stabilizer coatings
which provide biocompatibility, high therapeutic drug
loading capability, stability in biological milieu, and proper
intracellular uptake by cancer cells. Crosslinked dextrancoated MNPs are recognized as an example of a nanoplatform
with multiple functions.30 The engineered structure of this
formulation maintains a targeting feature and diagnostic
imaging properties for MRI, optical, and positron emission
tomography modalities. Many important formulations have
been developed and the iron oxide nanocore stabilized with
a double layer coating has frequently proved to be feasible
for theranostic purposes.31,32 However, these formulations
usually exhibit a higher hydrodynamic diameter in aqueous
medium ($250 nm) which limits their use as efficient
therapeutic carriers for medicinal applications. Therefore,
herein, a rationally designed MNP with improved features
was developed. This formulation was composed of an iron
oxide core coated with β-cyclodextrin (CD) and pluronic F68
polymer (polyethylene oxide-co-polypropylene oxide-copolyethylene oxide) that allows loading of anticancer drugs
(in this study, CUR). This formulation was examined for its
anticancer properties, magnetic targeting, and MRI in triplenegative breast cancer (MDA-MB-231) cells.

Materials and methods
Chemicals and cell culture
All chemicals and reagents were purchased from SigmaAldrich Corporation (St Louis, MO) unless otherwise
specified. Difco ® bacto-nutrient agar dehydrated was
purchased from BD Diagnostics (Franklin Lakes, NJ).
Milli-Q® purified water (Millipore Corporation, Billerica,
MA) was used to make all aqueous solutions. MDA-MB-231
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breast cancer cells were kindly gifted by Dr W Keith
Miskimins (Cancer Biology Research Center, Sanford
Research/University of South Dakota, Sioux Falls, SD).
This cell line was maintained as monolayer culture in
Dulbecco’s modified Eagle’s medium (high glucose; Thermo
Scientific HyClone, Logan, UT) supplemented with 10%
fetal bovine serum (Atlanta Biologicals Inc, Lawrenceville,
GA) and Gibco® 1% penicillin-streptomycin (Invitrogen
Life Technologies, Carlsbad, CA) at 37°C in a humidified
atmosphere (5% carbon dioxide).

Preparation of MNP and MNP-CUR
formulations
Iron oxide nanoparticles were prepared using a minor
modification of a protocol reported by Yallapu et al.22 Briefly,
100 mg of CD and 45 mL of water containing 810 mg of
iron(3+) and 297 mg of iron(2+) ions (molar ratio 2:1)
was placed in a 100 mL beaker. To this solution, 3 mL of
ammonium hydroxide (28% ammonia in water) was slowly
added at a stirring speed of 900 rpm. After 6 hours, 200 mg
of pluronic polymer F68 (average molecular weight 8350)
in 5 mL water was added to the nanoparticle suspension and
stirred overnight. After five washes with water,33 the nanoparticles were resuspended in 25 mL water and centrifuged
at 1000 rpm to remove larger aggregates. This formulation
was designated as MNP.
To load CUR in the MNPs, 1 mg CUR in 200 µL acetone
was added dropwise to 2.75 mL of an aqueous dispersion
of MNPs (10 mg). The mixture was stirred overnight at 400
rpm on a magnetic plate to facilitate the penetration of CUR
molecules into the CD or CD-F68 polymer layers in the
formulation. The drug-loaded nanoparticles were washed
three times by resuspending them in water and separated with
the help of magnets.33 These drug-loaded nanoparticles were
dispersed in 2 mL sterile phosphate buffered saline (PBS)
solution and stored in a refrigerator until further use. This
formulation was designated as MNP-CUR. The CUR loading
estimation was determined using an ultraviolet-visible
(UV-Vis) spectrophotometer (BioMate™ 3; Thermo Fisher
Scientific, Pittsburgh, PA) at 450 nm, following a previously
reported procedure.18,22

Characterization
A transmission electron microscope (TEM) (1210; JEOL
Ltd, Tokyo, Japan) was employed to determine the size and
morphology of the MNP-CUR nanoparticles. For this study, a
sample was prepared by placing the nanoparticle suspension
(50 µL of 1 mg/mL) on a 200 mesh formvar-coated copper
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TEM grid (grid size: 97 µm; Ted Pella Inc, Redding, CA).
The excess was removed using a piece of fine filter paper
and the grid was allowed to air dry prior to imaging under
the microscope operating at 80 kV.
The particle size, distribution, and zeta potential in
aqueous medium of the MNP-CUR formulation (50 µL
of 500 µg/mL dispersed in 3 mL of distilled water and
ultrasonicated for 30 minutes) were determined by employing
a Delsa™ Nano C particle size analyzer (Beckman Coulter,
Brea, CA). Particle size and distribution was measured for
3 minutes, and the zeta potential was measured for 90 runs
(9 minutes).
Fourier transform infrared (FTIR) spectral study was
conducted for dry MNP and MNP-CUR (obtained by
lyophilization using a Labconco Freeze Dry System, −48°C,
133 × 10−3 mbar; Labconco Corporation, Kansas City, MO).
The FTIR of nanoparticles was recorded at a scanning
speed of 4 cm-1 between 4000–750 cm−1 (32 scans) on
an IlluminatIR™ FT-IR microscope (Smiths Detection,
Danbury, CT).

In vitro CUR release
CUR release from the MNP-CUR formulation was carried
out in a PBS (154 mM, pH 7.4) solution containing 0.1%
weight/volume Tween-80® (Sigma-Aldrich) at 37°C at 100
rpm in an orbital shaker (Max Q™ 4000 series; Thermo
Fisher). Briefly, 2 mg of MNP-CUR was suspended in 3 mL
PBS solution in a 5 mL tube. At predetermined intervals,
the tube was centrifuged at 10,000 rpm for 30 minutes and
supernatant was stored at 4°C in the dark. Then fresh buffer
solution was replaced in the tube to redisperse the pellet.
The collected supernatants were measured for absorbance at
450 nm using a UV-Vis spectrometer as described earlier.22
An identical standard of CUR (0–10 µg/mL) was prepared
and absorbance was measured at 450 nm using the UV-Vis
spectrometer to estimate the amount of CUR released from
MNP-CUR.

Nanoparticles cellular uptake
A stable nanoformulation is determined by its cellular
uptake which is one of the important parameters for drug
delivery applications. To verify this phenomenon, the
uptake capacity of MNP-CUR formulation was evaluated
in MDA-MB-231 cancer cells. Cells (5 × 105) were seeded
in six-well plates in 2 mL medium. After 24 hours, media
was replaced with medium containing 0–30 µM MNP-CUR.
After 6 hours incubation time, cells were washed twice with
PBS and stained with Prussian blue to detect iron presence
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in the cancer cells.34 Cell images were captured using an
EVOS® phase contrast microscope (Advanced Microscopy
Group, Bothell, WA).
To further validate this cellular uptake (internalization)
behavior of MNP-CUR, TEM was employed. This study
provides clear evidence of the presence of nanoparticle
internalization at higher magnification. For this experiment,
1 × 107 cells per 150 mm plate were incubated with 20 µM
of MNP-CUR in 20 mL media for 6 hours. These cells
were centrifuged to remove unbound or uninternalized
nanoparticles, fixed with standard ice cold formaldehyde
(4%)-glutaraldehyde (1%) fixative solution followed by
osmium tetroxide fixative solution, and imaged under TEM,
following a previously published method.22

Protein adsorption
The protein adsorption on the surface of MNP-CUR was
evaluated following a developed protocol.35 For this ex
vivo study, 20 µL of human or mouse serum was added to
MNP-CUR formulation (1 mg/mL) and stirred for 2 hours at
25°C. The serum-bound MNP-CUR formulation pellet was
collected after centrifugation at 10,000 rpm for 30 minutes.
The MNP-CUR pellet was redispersed in 3 mL water and
measured for particle size using a particle size analyzer and
TEM as described above.

In vitro cytotoxicity

Methyl tetrazolium salt (MTS) assay
To assess in vitro cytotoxicity of CUR and MNP-CUR,
a standard MTS (3-[4,5-dimethyl-2-yl]-5-[3-carboxy
methoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium) cell
proliferation assay (CellTiter 96® AQueous; Promega
Corporation, Madison, WI) was employed. For this assay,
MDA-MB-231 cells (5000 cells/well in 100 µL media) were
seeded in 96-well plates and allowed to attach overnight. Cells
were then incubated with desired concentrations (5–40 µM)
of CUR/MNP-CUR for 2 days. Equivalent amounts of
dimethyl sulfoxide (DMSO) or MNP in PBS served as
controls for this experiment. After 2 days, the media was
replaced with fresh media (100 µL) and MTS reagent (25 µL)
in each well. After 2 hours, the color intensity resulting from
the formation of soluble formazan product was measured
at 492 nm using a microplate reader (BioMate 3 UV-Vis
spectrophotometer). This absorption reading is directly
proportional to the number of live cells in the culture. The
percentage of cell growth was presented as the percentage
of the absorption of treated cells to the absorption of nontreated cells. Data presented are from six replicates.
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Colony formation assay
Colony formation assay was employed to determine the longterm anticancer potential of the CUR/MNP-CUR formulation.
In brief, MDA-MB-231 cancer cells were seeded at a density
of 1000 per well in six-well plates in 2 mL medium and
allowed 2–3 days to begin formation of colonies. Then,
cells were treated with different concentrations (4–8 µM)
of CUR or MNP-CUR over a period of 10 days. The plates
were washed three times with PBS, fixed in chilled methanol,
stained with hematoxylin (Thermo Fisher), washed with tap
water and air dried. The density of colonies was counted
according to a previous method using a Multimage™ light
cabinet (Alpha Innotech Corporation, San Leandro, CA)
with the help of AlphaEaseFC™ (Alpha ImagerHP AIC)
software.18,21 The percent density of colonies was calculated
using the density of colonies formed in treatment divided by
the density of colonies formed in DMSO or MNP in PBS.
Data presented are from triplicate studies.

Mitochondrial membrane potential
The loss of mitochondrial membrane potential is a direct
indication of the apoptosis. This can be detected by a cationic fluorescent red-orange dye, tetramethyl rhodamine
ethyl ester (TMRE; Invitrogen). For this experiment, MDAMB-231 cells (1 × 106) were seeded in a 100-mm Petri dish
and allowed to attach overnight. These cells were exposed to
medium containing 5 µM and 10 µM CUR or MNP-CUR and
incubated for 24 hours at 37°C. Cells treated with DMSO and
MNPs without CUR in medium served as controls. The cells
were then washed twice with PBS and incubated with 100 nM
TMRE for 20 minutes at 37°C in medium without phenol
red. After completion of the incubation period, cells were
washed twice with PBS, trypsinized, and collected in 1 mL
medium containing hydroxyethyl piperazineethanesulfonic
acid without phenol red. Cell images were captured using an
Olympus® 1X71 microscope equipped with a DP71 camera
(Olympus Corporation, Tokyo, Japan). Quantitative TMRE
fluorescence stain in mitochondria was detected by injecting
25 µL cell suspension into an Accuri® C6 flow cytometer (BD
Accuri Cytometers, Ann Arbor, MI) to determine the mean
fluorescence levels in the FL2 channel. The experiment was
conducted in triplicate.

Reactive oxygen species (ROS)

For this experiment, MDA-MB-231 cells (1 × 106) were
plated in a 100-mm Petri dish and allowed to attach
overnight. Then the medium was replaced with medium
containing 5 µM and 10 µM CUR or MNP-CUR and
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incubated for 24 hours at 37°C. Cells treated with DMSO
and nanoparticles without CUR in medium served as
controls. After that, these cells were washed twice with
PBS and treated with 5 µM MitoSOX™ Red mitochondrial
superoxide indicator (Invitrogen) for 20 minutes at 37°C in
medium without phenol red. MitoSOX is rapidly oxidized
by superoxide and this complex is highly fluorescent upon
binding to nucleic acid. Cell images were taken using an
Olympus 1X71 microscope equipped with a DP71 camera.
The production of ROS was detected by injecting 25 µL cell
suspension into an Accuri C6 flow cytometer to determine the
mean fluorescence levels in the FL2 channel. The experiment
was conducted in triplicate.

In vitro MRI
MNP and MNP-CUR formulations were diluted in 3% agar
solution and final concentration of formulations in agar
solution was kept between 10–40 µg iron/mL. MRI experiments were performed at 25°C with a 9.4 T (400 MHz H1),
89 mm vertical bore MRI scanner equipped with triple axis
gradients (100 G/cm) and a 4-cm Millipede transmit/receive
radiofrequency coil (Agilent Technologies, Santa Clara, CA).
Tubes containing formulations in agar solution were placed
into the MRI scanner and a number of spin-echo sequences
were run to determine both T1 and T2 relaxation times. T2
relaxation time was measured using a spin-echo nuclear
magnetic resonance spectra analysis sequence with 32 echo
times arrayed exponentially from 5–300 milliseconds and
the repetition time of 8000 milliseconds. Similarly, the T1
relaxation time was measured by varying repetition times
between 100–6400 milliseconds while keeping the echo time
constant at 8 milliseconds. Relaxation rates R1 (1/T1) and
R2 (1/T2) were calculated by monoexponential curve fitting
of the signal intensity versus time (echo time or repetition
time) using Origin® 6.1 software (OriginLab Corporation,
Northampton, MA). Equations (1) and (2) were used for
curve fitting of relaxation rates R1 and R2, respectively:36
R1 = A × [1 – exp (−R1 × TR)]

(1)

R2 = A + C × [exp (−R2 × TE)]

(2)

T1 relaxivity (r1) and T2 relaxivity (r2) were calculated from
the slope of plot of R1 versus iron concentration and R2 versus
iron concentration in agar gels, respectively. TR represents
repetition time and TE represents echo time.

Magnetic targeting
Magnet-mediated delivery, ie, magnetic drug targeting, can
increase cellular uptake of nanoparticles in cancer cells and
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improve localized delivery of the encapsulated drug. For
magnetic drug targeting, MDA-MB-231 cells (2 × 105) were
seeded in six-well plates and allowed to attach overnight. The
following day, cells were treated for 3 hours with 2.5, 5, and
7.5 µM of CUR or MNP-CUR or MNP-CUR in the presence
of a neodymium external magnet (1″ Dia x 3/32″ thick Rare
Earth Magnet Disc; Amazing Magnets, Irvine, CA). Cells
treated with DMSO, MNP, and MNP with magnet served
as controls. Cells were then washed with PBS three times
to remove unbound and uninternalized CUR/MNP-CUR.
Medium without phenol red was added to the dishes to image
using a fluorescence microscope (Olympus 1 × 71). After
imaging, cells were collected in 1 mL medium by harvesting with trypsin and analyzed for semiqualitative cellular
uptake of CUR and MNP-CUR using flow cytometry.19,21,22
The inherent fluorescence property of CUR was utilized to
evaluate cellular uptake.

Statistical analysis
The data was processed using Microsoft Excel 2007 software
and presented as mean ± standard error of the mean. Statistical
analyses were performed using an unpaired, two-tailed
Student’s t-test. The level of significance was set at *P , 0.05.
All graphs were plotted using Origin 6.1 software.

Results and discussion
Nanotheranostics is a multidisciplinary approach in medicine
composed of therapy and imaging/diagnostic applications.25,26
To achieve such multiple functions in a single nanoformulation,
a multidisciplinary collaborative expertise involving
chemistry, drug delivery, materials science, and biological
sciences is required. MNPs are considered one of the
important materials for theranostic applications due to
their inherent low particle size, high magnetization values,
biocompatibility, and ability to load biomolecules or drug
molecules.24 Therefore, development of monodispersed MNPs
is essential for biomedical applications. Numerous methods
have been developed following various coating approaches
to fabricate magnetic nanoformulations with well-defined
particle size and shape.37,38 These approaches still need to
overcome destabilization mechanisms such as Ostwald
ripening, flocculation, phase inversion, and creaming. To
improve the features of these magnetic nanoformulations,
a simple precipitation approach was designed where an
iron oxide nanoparticle core was prepared in the presence
of CD and subsequently coated with pluronic polymer
F68 (poly[ethylene-co-propylene glycol]) (Figure A1,
Appendix). CD selection in this formulation was based
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B

C
Differential intensity (%)

A

Figure 1A illustrates the hypothetical single nanoparticle
layer structure of MNP-CUR formulation where CUR drug
molecules are positioned in CD layer(s). The TEM image of
MNP-CUR demonstrates individual nanoparticle grains had
an average size of about 9 nm (Figure 1B). Dynamic light scattering data of MNP-CUR reveals the particles aggregative size
averaged 123 nm (Figure 1C) with unimodal and narrow size
distribution, and contained a polydispersity index of 0.172.
This indicates minimal change in particle aggregative size
after CUR loading in MNP formulation (ie, MNP formulation
aggregative particle size was 116 nm; Figure A1, Appendix).
In addition, overall aggregative particles can be seen in low
magnification TEM images which detect average aggregative
size of nanoparticles .120 nm (Figure A1B, Appendix). The
average hydrodynamic particles size of MNP-CUR (123 nm)
was considerably smaller than various multilayer iron oxide
formulations prepared by coprecipitation approaches.31,40 The
physical stability of a nanoparticle solution can be predicted
by the zeta potential of the formulation. The zeta potential of
the MNP-CUR formulation was −0.66 mV which allows good
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upon its combination of hydrophilic units (-OH) which can
bind to the iron oxide nanoparticle surface and is capable of
including anticancer drug(s) via the hydrophobic cavity.21,39
Additional coating with F68 polymer results in a hydrophobic
(polypropylene, polypropylene oxide) chain which can
bind to the hydrophobic cavities of CD and the hydrophilic
(polyethylene glycol, polyethylene oxide) chain provides
additional hydrophilicity and stability to particles. 22,40,41
CD and F68 polymer coating resulted in reduction of the
nanoparticle aggregation phenomenon (Figure A1, Appendix).
Similar patterns of decreased nanoparticle aggregation were
observed in dynamic light scattering particle size analysis, ie,
the aggregative particle size of nanoparticles decreased from
208 nm to 116 nm (Figure A1, Appendix). However, the size
of the individual nanoparticle grain remained unchanged.
The diameter of particles observed in TEM was smaller
than that detected by the dynamic light scattering method
because TEM observations were of the nanoparticles in dry
form while dynamic light scattering observations were of the
nanoparticles in aqueous suspensions.

10

20

30

Time (day)

Wavenumber (cm−1)
Figure 1 Physicochemical characterization of curcumin-loaded magnetic nanoparticle formulation. (A) Hypothetical schematic representation of curcumin-loaded single
magnetic nanoparticle formulation. (B) Transmission electron microscopic image of curcumin-loaded magnetic nanoparticle formulation. Data show an individual particle
grain size of ∼9 nm. (C) Dynamic light scattering measurement of curcumin-loaded magnetic nanoparticle formulation. Data demonstrates the average nanoparticle aggregative
size is 123 nm. Data represents the average of three replicates. (D) Fourier transform infrared spectra of magnetic nanoparticle formulation, curcumin, and curcumin-loaded
magnetic nanoparticle formulation. Data was obtained for dry powder samples. (E) In vitro curcumin release from curcumin-loaded magnetic nanoparticle formulation. Inset
tubes depict curcumin release at different time points (0.4–28 days). Data represents the mean ± standard error of the mean for three repeats.
Abbreviations: CUR, curcumin; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; NP, nanoparticle.
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A

MNP-CUR treatment (µM)
0
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Control
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B

N

MNP-CUR treated
MDA-MB-231 cancer cells
N

N

N

N
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N
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N
N
N

N

N

N

2 µm
Figure 2 Curcumin-loaded magnetic nanoparticle formulation improves curcumin cellular uptake. (A) Phase contrast images of MDA-MB-231 cancer cells treated with
curcumin-loaded magnetic nanoparticle formulation (0–30 µM). The intensity of blue stain produced by Prussian blue from the iron of curcumin-loaded magnetic nanoparticle
formulation helps improve visualization of internalized nanoparticles of curcumin-loaded magnetic nanoparticle formulation. White arrows highlight less internalization of
nanoparticles and red arrows indicate greater accumulation of nanoparticles. (B) Transmission electron microscopic images of free MDA-MB-231 cells and MDA-MB-231 cells
incubated with curcumin-loaded magnetic nanoparticle formulation (20 µM) for 6 hours. Black arrows indicate the accumulation and internalized nanoparticles (curcuminloaded magnetic nanoparticle formulation) and red arrows represent the vacuole and lysosomal activity which induces apoptosis.
Abbreviations: MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; N, nucleus.

stability during storage. The slightly negative zeta potential
was attributed to the F68 polymer. Because the zeta potential
for nanoparticles in solution is a slightly negative value, the
nanoparticles may likely repel each other resulting in less
aggregation. A similar observation was found in the case of
oleic acid-F127 pluronic polymer-stabilized MNPs.41
The chemical difference between MNP and MNP-CUR
formulations was evaluated by FTIR analysis (Figure 1D).
FTIR of MNPs (black color spectrum) clearly showed a
broad peak between 3600–3050 cm-1 due to the presence of
hydroxyl groups of iron oxide core/CD/F68 polymer, and an
intense band at 1010 cm-1 due to glycosidic C–O–C vibration
of CD and F68 polymer.21,32,40,42 FTIR analysis of CUR (red
color) revealed peaks at: 1610 cm-1 and 1500 cm-1 due to
C=C and C=O of benzene ring, respectively, 1438 cm-1 due
to olefinic C–H bending vibration, 1280 cm-1 due to aromatic
C–O stretching vibrations, and 985 cm-1 due to C–O–C
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stretching vibrations. FTIR spectrum of the MNP-CUR
formulation demonstrated peaks related to CUR, in addition
to MNP related peaks, that are consistent with the authors’
previous reports (on poly[lactic-co-glycolic acid]-CUR
nanoparticles and CD-CUR nanoassemblies) and published
literature.19,21,43,44
The loading efficiency of therapeutic drugs in nanoparticles directly influences the therapeutic outcome of the
system. CUR is a known anticancer and chemopreventive
molecule.8 However, its use is limited due to its low bioavailability and poor pharmacokinetics. Therefore, a MNP-CUR
nanosystem was developed to increase the bioavailability,
pharmacokinetics and subsequently improve the therapeutic
efficacy of CUR. The dual layer MNP formulation permitted
loading of 94.2 µg of CUR per mg of nanoparticles. This
level of drug loading was likely achieved because the
presence of a CD layer shell at the interface of the MNP
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core and F68 polymer chains may prevent the diffusion
of CUR.21,45,46 Figure 1E demonstrates the release profile
of CUR from MNP-CUR under in vitro conditions. A slow
and sustained release of CUR from MNP-CUR was noticed
throughout the study (for 28 days). About 47% CUR release
occurred in the first 5 days. Therefore, this data clearly supports the proposition that CUR release is highly controlled
by the CD layer. Since CUR is a hydrophobic molecule, it
therefore remains in the CD layers (hydrophobic cavity)
rather than transfer to the aqueous phase. Additionally,
the F68 polymer chains (polypropylene oxide units) may
also restrict the release of CUR into aqueous medium.
Therefore, the MNP-CUR formulation exhibited controlled
and sustained release of CUR which may ensure its efficient
anticancer activity and prevent the cancer from developing
drug resistance.47

Cellular uptake
Improved intracellular accumulation or uptake of drug
nanoparticles in cancer cells is an indication for a higher
therapeutic index.16 Therefore, this step of the present
study investigated the qualitative uptake of MNP-CUR
by MDA-MB-231 cells. The uptake of MNP-CUR was
visualized by Prussian blue staining. A clear accumulation
pattern of MNP-CUR was observed in MDA-MB-231 cancer
cells: accumulation increases as the MNP-CUR concentration
increases (faint blue [white arrows] to dark blue [red arrows];
Figure 2A). The internalized particles localized in almost
every cell and throughout the cell components. This type of
formulation showed very minimal uptake by macrophages,
which supports increased circulation time for a more
effective therapy.22,41 It is also logically possible to improve
the internalization capacity of this type of nanoparticle by
a ligand/antibody/penetrating peptide.48 Their high affinity
allows preferential internalization through receptor mediated
endocytosis; in this manner nanoparticle(s) efficiently target
cancer cells.
To further prove MNP-CUR intracellular localization in
MDA-MB-231 cancer cells, a TEM study was performed.
In this study, after 6 hours treatment with MNP-CUR,
MDA-MB-231 cancer cells were cross-sectioned (90 nm)
using an ultramicrotome and viewed under TEM according
to a previously reported method.19 Interestingly, most of the
MNP-CURs were located as clusters in the cell structure,
a phenomenon which was completely absent in control
cells (Figure 2B). A magnified view of MNP-CUR uptake
is also presented in Figure A2, Appendix. Therefore, it is
clear that MNP-CURs underwent endocytosis but were not
physically bound to the cancer cell surface. The authors
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propose that the entrapped MNP-CUR will demonstrate its
anticancer properties by delivering CUR more efficiently to
cancer cells. Control cancer cells were not affected at ultrastructural level and did not show any changes in cellular
integrity. However, it is very clear that cancer cells treated
with MNP-CUR exhibit ultra-structural changes, including
shrinkage in nucleus, vesicle, and vacuole formation which
represent onset of apoptosis.19,49

Protein binding
The final aim is to develop MNP-CUR for preclinical
and human applications. Serum protein quickly binds to
the surface of nanoparticles and changes their fate before
reaching the intended target(s). This binding affinity of
protein may depend on particle size and surface properties
of the nanoparticles.49 Properties (in this case particle size)
of stable drug nanoformulations may not be affected by the
protein absorption during circulation in blood. To check
this phenomenon, MNP-CUR formulation was incubated
with human and mouse serum, and their particle size was
measured using TEM and dynamic light scattering. Figure 3A
demonstrates no significant change in the aggregation of
MNP-CUR formulation before and after incubation with
human serum and mouse serum. However, there was a
slight change in the surface morphology when incubated
with mouse or human serum. Similarly, a slight increase
in particle size was observed after incubation with mouse
or human serum (MNP-CUR-mouse serum, 136 nm;
MNP-CUR-human serum, 144 nm) compared to control
nanoparticles (MNP-CUR, 123 nm) (Figure 3B). The increase
in particle size may be attributed to the adsorbed layers of
serum proteins.50

Anticancer potential
It is imperative to assess the cytotoxicity of developed
MNP-CUR for its potential anticancer application(s).
The evaluation of cytotoxic activity was performed by
direct observation of cell morphology as well as MTS
assay. Evaluation by two different methods was conducted
because some recent reports suggest that cytotoxicity assay
reagents may interfere with nanoformulations.51,52 Cell
image/morphology evaluation (Figure 4A) and MTS assays
(Figure 4B) provide a direct qualitative and quantitative
assessment of the anticancer potential of CUR/MNP-CUR
formulations. When cells were treated with CUR, the viability
of the cancer cells decreased sharply in a concentration
(10–30 µM)-dependent manner (Figure 4A). A similar pattern
was observed with MNP-CUR at all tested concentrations
(Figure 4A). Interestingly, cell morphology was drastically
International Journal of Nanomedicine 2012:7
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Figure 3 Curcumin-loaded magnetic nanoparticle formulation particle size is not influenced by human and mouse serum protein adsorption. (A) Curcumin-loaded magnetic
nanoparticle formulation particles morphology viewed under transmission electron microscope before and after incubation with human and mouse serum. (B) Particle size
of curcumin-loaded magnetic nanoparticle formulation before and after incubation with human and mouse serum.
Abbreviation: MNP-CUR, curcumin-loaded magnetic nanoparticle formulation.
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Figure 4 Curcumin-loaded magnetic nanoparticle formulation treatment increases the anticancer potential in MDA-MB-231 cells. (A and B) Cells were treated with different
concentrations (5–40 µM) of curcumin or curcumin-loaded magnetic nanoparticle formulation; medium was changed on day two. (A) Representative phase contrast images of MDAMB-231 cells treated with vehicle (dimethyl sulfoxide or magnetic nanoparticles) and 10–30 µM curcumin or 10–30 µM curcumin-loaded magnetic nanoparticle formulation. Images
obtained at 2000×. (B) Cell viability was measured using methyl tetrazolium salt assay using an ultraviolet-visible spectrophotometer at 492 nm. Data is mean ± standard error of the
mean (n = 6). Dimethyl sulfoxide and magnetic nanoparticle formulation controls did not show any effect at these concentrations. (C and D) Cells were treated with either 4–8 µM
of curcumin or curcumin-loaded magnetic nanoparticle formulation for 10 days. (C) Representative images of colonies stained with hematoxylin. (D) Colony density was counted
and expressed as a percent of the control. Data represent mean of triplicate for each treatment (mean ± standard error of the mean). *P , 0.05 for significance difference.
Abbreviations: CUR, curcumin; DMSO, dimethyl sulfoxide; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; NPs, nanoparticles.

International Journal of Nanomedicine 2012:7

submit your manuscript | www.dovepress.com

Dovepress

Powered by TCPDF (www.tcpdf.org)

1769

Dovepress

Yallapu et al

changed and the number of cancer cells was greatly reduced
even at 10 µM MNP-CUR. A very limited number of cancer
cells were observed after treatment with 20 µM and 30 µM
of CUR/MNP-CUR. CUR/MNP-CUR-treated cells were
clearly distinguished with plasma membrane smoothing,
blebbing, and loss of spindle morphology, and were almost
detached, which is an apoptosis feature. Treatments with
various CUR and CUR nanoformulations also have reported
this apoptosis feature in the number of cancer cells.16,23 The
MTS assay data demonstrated a concentration-dependent
antiproliferative effect (5–40 µM) by CUR and MNP-CUR
formulations (Figure 4B) as observed in the study of cellular
images. The half maximal inhibitory concentration (50% cell
growth inhibitory concentration) was calculated as 17.2 µM
with CUR and 12.4 µM with MNP-CUR treatment. From
this data, it can be concluded that although CUR release
from MNP-CUR formulation was only 40%, it is as equally
potent as free CUR in suppressing cell growth. Therefore,
the MNP-CUR formulation can be employed as an efficient
cancer therapeutic agent.
To further prove that the MNP-CUR formulation holds
improved anticancer therapeutic potential, a propidium
iodide stain experiment was performed. Propidium iodide
specifically binds to double-stranded DNA through the
plasma membrane of nonviable cells which can be detected
in flow cytometry in the FL2 channel. MNP-CUR-treated
cells indicate a significant propidium iodide stain over CURtreated cells, suggesting a higher number of dead cells exist
after MNP-CUR treatment (Figure A3, Appendix). This data
supports the findings of MTS assay.
The authors’ hypothesis is that since CUR releases
slowly from MNP-CUR, this formulation may exhibit a
superior anticancer activity in long term experiments such
as colony formation assays. For example, magnetoplasmonic
assembly of the polyethylene glycol-CUR formulation
demonstrates better anticancer properties after 42–52 hours
treatment compared to magnetoplasmonic assembly-CUR/
CUR treatment and the efficacy depends on the drug release
pattern.49 This supports the belief that CUR nanoformulations
require time to show superior effects. Therefore, the efficacy
of MNP-CUR on MDA-MB-231 cancer cells was studied.
A significant decrease was observed in the formation of
colonies after MNP-CUR treatment compared to CUR
(Figure 4C). CUR treatment gradually declined formation
of colony density, ie, 4–8 µM concentration was responsible
for reducing colony density from ∼100% to 38% (Figure 4D)
whereas 4 µM MNP-CUR treatment successfully restricted
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colony density to merely 16% (Figure 4D). This result clearly
indicates that the increased cytotoxicity (reduced colony
density) was primarily associated with active CUR release
from MNP-CUR over time. A similar improved anticancer
effect in a number of cancer cell lines was observed in
previous studies using various CUR formulations.18–20
These studies support this enhanced anticancer potential
by documenting an increase in apoptosis as demonstrated
through enhanced cleaved poly(adenosine diphosphate
ribose) polymerase protein with MNP or other CUR
nanoformulations.18–20

Mitochondrial membrane potential
The loss of mitochondrial membrane or mitochondrial
dysfunction is a key indicator of intrinsic apoptosis.42 The
specificity of mitochondrial stain after 24 hours treatment
with CUR and MNP-CUR formulations was detected using
cationic dye TMRE by fluorescence microscopy and flow
cytometry. TMRE accumulates in the mitochondria when
a membrane has intact potential. TMRE positive cells are
an indication of viable cells with high membrane potential.
Decrease in TMRE stain indicates a loss of mitochondrial
membrane potential. Microscopy analysis illustrated that
upon treatment with 5 µM CUR, the cells had a very similar
amount of stain as control cells; however, after treatment with
10 µM CUR, the cells showed a significant decrease in stain
intensity (Figure 5A). In the case of MNP-CUR, both 5 µM
and 10 µM treatments showed decreased stain, indicating
effective mitochondrial membrane damage and thus increased
anticancer potential (Figure 5A). Similar results were observed
with flow cytometry analysis. A significant decrease in TMRE
stain was noticed with MNP-CUR treatment compared to
CUR (Figure 5B). This may be due to higher cellular uptake
of MNP-CUR, inducing greater loss in membrane potential.

ROS production
Many anticancer drug treatments lead to the generation of
ROS which is involved in stimulating inflammation, apoptosis, and DNA damage which can affect the signaling pathways
involved in external or internal cell damage.53,54 Although
CUR is a potent antioxidant with ROS scavenger characteristics, it also induces ROS production in human tumor
cells.55 A MitoSOX stain was used to identify such intracellular mitochondrial ROS generation from the CUR-treated
and MNP-CUR-treated cells. ROS production in the CURtreated cells was not significantly different from control cells.
However, the production of ROS was significantly increased
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Figure 5 Curcumin-loaded magnetic nanoparticle increases loss of mitochondrial membrane potential. MDA-MB-231 cells (1 × 106) were treated with curcumin and
curcumin-loaded magnetic nanoparticles (0–10 µM) for 24 hours and the loss of mitochondrial membrane potential was determined using tetramethyl rhodamine ethyl
ester dye. (A) Representative tetramethyl rhodamine ethyl ester stain in MDA-MB-231 cells after treatment with curcumin and curcumin-loaded magnetic nanoparticle
formulation. Less intense stain indicates loss of mitochondrial membrane potential. (B) Quantitative estimation of tetramethyl rhodamine ethyl ester stain was analyzed by
flow cytometry. For this analysis, 10,000 cells were injected into an Accuri® C6 Flow Cytometer (BD Accuri Cytometers, Ann Arbor, MI) and fluorescence levels were
measured in the FL2 channel. Data represent the mean of three repeats for each treatment (mean ± standard error of the mean). *P , 0.05 for significance difference.
Abbreviations: CUR, curcumin; DMSO, dimethyl sulfoxide; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation;
RFU, relative fluorescence units.

in MNP-CUR-treated cells (Figure 6A and B). These results
further demonstrate that MNP-CUR can efficiently internalize
and deliver CUR in its active form and is responsible for ROS
production, while free CUR barely influences the production
of ROS at the tested concentrations. The obtained results
corroborate similar findings reported by Mulik et al56 that
CUR nanoparticles potentiate apoptosis in MDA-MB-231
cancer cells via generation of ROS. Similarly, pretreatment
and cotreatment of CUR nanoparticles with other anticancer
drugs also leads to an increase in ROS production.57,58

MRI
MNPs exhibit specific inherent magnetic properties that are
highly important in MRI for increasing the detection limits
in tissue lesions within the body.24,25,38 In addition, surfacemodified MNPs avoid recognition by the reticuloendothelial
system and therefore may efficiently target tumors, making
them a better contrast imaging agent. In this study, the suitability of MNPs and the MNP-CUR formulation as contrast
imaging agents for MRI was investigated.26,38 Figure 7A
illustrates an increase of nanoparticle concentration resulting
in a reduction in T2-weighted signals. Calculated transverse

International Journal of Nanomedicine 2012:7

relaxation times from images (Figure 7A) relative to the control gel decreased with an increase in nanoparticle concentration (Figure 7B). Specifically, as the concentration increased
from 10 µg iron/mL to 40 µg iron/mL, T2 relaxation times
decreased from 22.4 milliseconds to 5.8 milliseconds. By
plotting the transverse relaxation rate R2 (1/T2) as a function
of the concentration of iron in each sample, R2 increased linearly with the concentration of iron (Figure 7C). From these
data, T2 relaxivity (r2) was calculated as 7.040 s−1 µg−1 mL for
MNP-CUR. The relaxivity was slightly diminished when the
particles were in the presence of cancer cells (4.38 s−1 µg−1 mL)
but enhanced values were observed in combination with CURnanoparticles. The relaxivity order detected was 7.040 s−1 µg−1
mL (MNP-CUR) . 4.38 s−1 µg−1 mL (MNP-CUR in cancer
cells) . 3.40 s−1 µg−1 mL (MNP) . 2.38 s−1 µg−1 mL (MNP in
cancer cells). A similar pattern was also observed in T1 relaxivity (r1): 33.21 s−1 µg−1 mL (MNP-CUR) . 18.663 s−1 µg−1 mL
(MNP-CUR in cells) . 11.303 s−1 µg−1 mL (MNP) . 6.389 s−1
µg−1 mL (MNP in cancer cells). The higher relaxivity values
of MNP-CUR are attributed to CUR and the nanoparticles
induce greater inhomogeneity in the magnetic field than MNP.
Similar improved enhanced contrast properties were observed
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Figure 6 Curcumin-loaded magnetic nanoparticle formulation induces more reactive oxygen species formation. MDA-MB-231 cells (1 × 106) were treated with curcumin
or curcumin-loaded magnetic nanoparticle formulation (0–10 µM) for 24 hours, and reactive oxygen species generation was determined using MitoSOX Red dye (Invitrogen
Life Technologies, Carlsbad, CA). (A) Representative reactive oxygen species generation images in MDA-MB-231 cells after treatment with curcumin and curcumin-loaded
magnetic nanoparticle formulation. (B) Quantitative estimation of reactive oxygen species generation was analyzed by flow cytometer. For this analysis, 10,000 cells were
injected into an Accuri® C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) and fluorescence levels were measured in the FL2 channel. Data represent the mean of
three repeats for each treatment (mean ± standard error of the mean). *P , 0.05 for significance difference.
Abbreviations: CUR, curcumin; DMSO, dimethyl sulfoxide; MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation;
RFU, relative fluorescence units.
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Figure 7 In vitro magnetic resonance image characteristics of magnetic nanoformulations. (A) Signal intensity T2-weighted magnetic resonance images of magnetic nanoparticle
formulation, magnetic nanoparticle formulation in MDA-MB-231 cancer cells, curcumin-loaded magnetic nanoparticle formulation, and curcumin-loaded magnetic nanoparticle
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Abbreviations: MNP, magnetic nanoparticle formulation; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation; TE, echo time.
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with drug-loaded formulations due to the color(s) contributed
by the drug(s), such as yellow (CUR) or red (doxorubicin).21,31,39
Previous reports support that these multilayer-coated MNPs
may have superior imaging characteristics over conventional
magnetic nanoformulations.40,41

Magnetic targeting
Ideal magnetic field mediated drug delivery (magnetic
targeted drug delivery) facilitates drug accumulation in
cells possibly by passive diffusion, adsorptive transcytosis,
and receptor mediation.59 This advanced drug targeting
approach is increasingly utilized due to increased site
specificity with fewer side effects.26 However, efficiency of
magnetic field-mediated cellular delivery of drug depends
on the applied external magnetic field as well as the type
of MNP carrier.25,38,60,61 To determine the potential utility
of the nanoformulations for possible magnetic targeting,
MDA-MB-231 cancer cells treated with MNP-CUR were
exposed to a neodymium external magnet for 3 hours.
A detailed schematic representation of the experiment
design is presented in Figure 8A. The results were evaluated
comparing CUR/MNP-CUR internalization in the cancer

A CUR treatment

cells. CUR (2.5–7.5 µM) exposed cells exhibited a
very minute amount of CUR. MNP-CUR-treated cells
demonstrated significant cellular uptake of CUR through
the influence of magnetic field (Figure 8B). This effect was
only minimal when there was no magnetic field applied
(Figure 8B). Overall, qualitative accumulation/cellular uptake
of CUR assessed by flow cytometry was clearly enhanced
by magnetic field (Figure 8C) at all the concentrations
tested. Thus, exposure to external magnets significantly
increased the cellular uptake of MNPs predominantly into
malignant cells. This study suggests that application of an
external magnetic field would enhance additional CUR
internalization, inducing more cellular apoptosis, thereby
increasing the possible cytotoxicity of MNP-CUR.
Overall, the data show the feasibility of using an
innovative nanoparticle system which combines magnetic
targeting of a therapeutic agent (CUR) with both magnetic
resonance and fluorescence imaging in a single system
(Figure 9). This formulation can be extended to other
clinically used therapeutic drugs and can be developed as
antibody conjugation features.41 Targeting efficacy of these
multifunctional nanoparticles specifically to triple-negative
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Figure 8 Curcumin-loaded magnetic nanoparticle formulation magnetic targeting improves curcumin uptake by MDA-MB-231 cells. (A) Schematic representation of
experimental design for magnetic targeting. Cells (2 × 105) were seeded in six-well plates and treated for 3 hours with 2.5, 5, and 7.5 µM of (1) curcumin, (2) curcumin-loaded
magnetic nanoparticle formulation, or (3) curcumin-loaded magnetic nanoparticle formulation in the presence of a neodymium external magnet. (B) Curcumin uptake by
cancer cells was visualized using a fluorescence microscope (1X71; Olympus Corporation, Tokyo, Japan). (C) Internalized fluorescence levels were analyzed using an Accuri®
C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) in the FL1 channel. Data represent the mean of three repeats for each treatment (mean ± standard error of the
mean) and expressed in fold change compared to respective controls. *P , 0.05 for significance difference.
Abbreviations: CUR, curcumin; MNP-CUR, curcumin-loaded magnetic nanoparticle formulation.
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breast cancer cells can be further enhanced clinically through
conjugation of monoclonal antibodies, such as antitransferrin (Figure A4, Appendix), glucose transporter 1, and folic
acid.62,63

Conclusion
Development of safe, efficient, and biocompatible drug
nanoformulations with theranostic properties is essential
for clinical translation in cancer therapy. A composite
MNP formulation composed of an iron oxide nanoparticle
core coated with CD and pluronic polymer (F68) with
CUR loading capability was developed. This formulation exhibited improved uptake in cancer cells, increased
loss of mitochondrial membrane potential, and produced
higher ROS, suggesting it is extremely valuable in anticancer therapeutics. Additionally, enhanced MRI properties (compared to conventional MNPs) demonstrate this
formulation has good imaging agent characteristics. More
importantly, magnetic targeting of MNP-CUR facilitated
an enhanced delivery of CUR to cancer cells. All together,
these findings indicate that this formulation is appropriate for utilization in engineered delivery systems for
theranostic applications in efficient image-directed cancer
therapeutics.
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Figure A1 Composition and particle size evaluation of magnetic nanoparticles. (A) Schematic representation of the synthesis route of a multifunctional magnetic nanoparticle.
Iron oxide (magnetic) nanoparticles prepared by chemical precipitation reaction in presence of β-cyclodextrin and subsequent F68 polymer coating leads to magnetic
nanoparticle nanoformulation. (B) Transmission electron microscopic image of pure iron oxide core nanoparticles (no coating with β-cyclodextrin/F68 polymer), iron oxide
nanoparticles coated with 100 mg of β-cyclodextrin, and iron oxide nanoparticles coated with 100 mg of β-cyclodextrin and 200 mg of F68 polymer. Data show an individual
particle grain size of ∼9 nm. (C) Dynamic light scattering particle size data of (1) pure iron oxide core nanoparticles, (2) iron oxide nanoparticles coated with β-cyclodextrin,
and (3) iron oxide nanoparticles coated with β-cyclodextrin and F68 polymer representing aggregative particles size in aqueous media.
Note: β-cyclodextrin and F68 polymer coating help to reduce particle aggregative phenomenon.
Abbreviations: CD-IOCNP, iron oxide core nanoparticles coated with CD (100 mg); F68-CD-IOCNP/MNP, iron oxide core nanoparticles coated with CD (100 mg) and F68
polymer (200 mg); IOCNP, iron oxide core nanoparticles.
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Figure A2 Magnified view of transmission electron microscopic images of MDA-MB-231 cells after treatment with curcumin-loaded magnetic nanoparticles (20 µM) for
6 hours. Accumulation of curcumin-loaded magnetic nanoparticles occurs throughout the cytoplasm.
Note: Red arrows represent nanoparticles accumulation.
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Figure A3 Curcumin-loaded magnetic nanoparticle formulation increases MDA-MB231 cell death. Cells (2 × 105) were seeded in six-well plates and treated for 24 hours
with 2.5, 5, and 7.5 µM of curcumin or curcumin-loaded magnetic nanoparticles. The
cells were collected both live and dead (floating) and incubated at room temperature
in the dark with 5 µL propidium iodide for 20 minutes in 2 mL medium containing
hydroxyethyl piperazineethanesulfonic acid without phenol red. After completion of
the incubation period, propidium iodide stain was quantified for 5000 cells using
an Accuri® C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) in the FL2
channel. The experiment was conducted in triplicate.
Abbreviations: CUR, curcumin; MNP-CUR, curcumin-loaded nanoparticles;
PI, propidium iodide.
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Figure A4 Antitransferrin-fluorescein isothiocyanate antibody conjugation promotes
magnetic nanoparticles targeting MDA-MB-231 cancer cells. Cells (2 × 105) were seeded
in six-well plates and treated for 24 hours with 50, 100, and 150 µg of antitransferrinfluorescein isothiocyanate antibody or magnetic nanoparticles conjugated with
antitransferrin-fluorescein isothiocyanate antibody. The cells were trypsinized and
collected in 1 mL medium containing hydroxyethyl piperazineethanesulfonic acid
without phenol red. Fluorescein isothiocyanate levels were analyzed for 5000 cells
using an Accuri® C6 flow cytometer (BD Accuri Cytometers, Ann Arbor, MI) in the
FL1 channel. The experiment was conducted in triplicate.
Note: Antitransferrin-fluorescein isothiocyanate conjugation was performed
according to previous protocol.19 In detail, 5 mg of magnetic nanoparticles and 1 mg
of eight-arm N-hydroxysuccinimide–polyethylene glycol–N-hydroxysuccinimide
linker (Nanocs Inc, Boston, MA) were dispersed in 1 mL phosphate buffered saline.
After 1 hour, 500 µg of antitransferrin-fluorescein isothiocyanate was mixed and
allowed to link onto magnetic nanoparticles overnight. To this mixture, 500 µg of
bovine serum albumin was added to nullify excess N-hydroxysuccinimide reactivity.
The conjugation efficiency was found to be 92%.
Abbreviations: MNP-transferrin-FITC, magnetic nanoparticles conjugated with
antitransferrin-fluorescein isothiocyanate antibody; RFU, relative fluorescence units;
transferrin-FITC, antitransferrin-fluorescein isothiocyanate antibody.
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